Prescribing information



ENERZAIR BREEZHALER is indicated as a maintenance treatment for asthma in adult patients not adequately controlled with a maintenance combination of a long-acting beta2-agonist and a high dose of an inhaled corticosteroid, who experienced one or more asthma exacerbations in the previous year.1


  1. ENERZAIR BREEZHALER Summary of Product Characteristics.


Rate this content: 
Average: 3.7 (3 votes)
UK | February 2021 | 103399

Ask Speakers


Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]